Logo

Innovent Reports First Patient Dosing in P-II Trial of IBI302 for Neovascular Age-Related Macular Degeneration

Share this

Innovent Reports First Patient Dosing in P-II Trial of IBI302 for Neovascular Age-Related Macular Degeneration

Shots:

  • The first patient has been dosed in the P-II trial assessing IBI302 in patients with active subfoveal or parafoveal choroidal neovascularization secondary to nAMD. The primary objective is to evaluate the efficacy and safety of IBI302
  • The two P- I studies of IBI302 (single/multiple-dose escalation) showed improvement in visual acuity with a reduction in retinal thickness- leakage- and total area of neovascularization in terms of efficacy
  • Additionally- the ongoing P-II study of the therapy will focus on improving visual acuity and retinal thickness and the effect on macular atrophy and fibrosis

  Ref: PRNewswire | Image: Innovent

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions